The causes of the broad spectrum of severity in COVID-19 are unknown. A protecting impact by humoral immunity from earlier infections by viruses of the SARS-CoV-2 household may clarify a light type of this illness. This examine aimed to deal with whether or not the presence of antibodies in opposition to human seasonal coronaviruses (HCoVs) may forestall extreme manifestations of COVID-19.
A cross-sectional examine was carried out in 165 members. The presence of pre-existent antibodies in opposition to the seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63 have been detected. From all the seasonal HCoVs studied, it was solely discovered that being seropositive to HCoV-229E introduced an affiliation (p = 0.012) with creating delicate medical signs of COVID-19 or being asymptomatic.
Multinomial regression evaluation confirmed that being seropositive to HCoV-229E is related to delicate or reasonable medical signs for COVID-19. Statistical evaluation additionally confirmed that being feminine is related to being asymptomatic for SARS-CoV-2 an infection or creating delicate COVID-19.
A subgroup evaluation taking solely seropositive to HCoV-229E revealed that females usually tend to develop asymptomatic SARS-CoV-2 an infection (OR = 27.242, 95% CI 2.092-354.706, p = 0.012). Our outcomes recommend that earlier infections by HCoV-229E may forestall extra critical medical manifestations of COVID-19, however these should not the one variables that affect this occasion.
The comparative efficacy and security of anti-CD20 monoclonal antibodies for relapsing-remitting a number of sclerosis: A community meta-analysis
With the latest profitable concentrating on of B lymphocytes in sufferers with a number of sclerosis (MS), therapy with anti-CD20 monoclonal antibodies (mAbs) might characterize a promising managemental strategy, significantly for these with relapsing/remitting MS (RRMS).
A community meta-analysis was carried out based mostly on a complete search in Embase, PubMed, and the Cochrane Library to evaluate the comparative efficacy and security of at present obtainable anti-CD20 monoclonal antibodies (mAbs), together with rituximab, ocrelizumab, and ofatumumab, versus a standard comparator (interferon beta-1a [INFβ-1a]) in RRMS sufferers recruited in randomized medical trials (RCTs).
In a frequentist community meta-analytical mannequin, annualized relapse charges (ARRs) and security outcomes have been expressed as threat ratios (RRs), whereas relapse-free occasions have been expressed as odds ratios (ORs). Remedy rating was carried out utilizing P-scores. The knowledge of proof was appraised utilizing the GRADE strategy.
5 publications reported the outcomes of seven RCTs (3938 sufferers, 67.09% females). In comparison with INFβ-1a, ocrelizumab lowered the chance of ARR (RR = 0.56, 95% CI, 0.50-0.64), critical adversarial occasions (RR = 0.17, 95% CI, 0.09-0.30), and therapy discontinuation as a consequence of adversarial occasions (SAEs, RR = 0.60, 95% CI, 0.39-0.93), and it was related to larger odds of no relapses (OR = 2.47, 95% CI, 2.00-3.05).
Ocrelizumab ranked finest amongst all different remedies by way of lowering ARR and SAEs. The standard of proof was low for ocrelizumab, low to reasonable for rituximab, and excessive for ofatumumab. Additional large-sized, well-designed RCTs are wanted to corroborate the efficacy and security of ocrelizumab and different anti-CD20 mAbs in RRMS.
Fc Receptor Variants and Illness: A Essential Issue to Contemplate within the Antibody Therapeutics in Clinic
The fragment crystallizable (Fc) area of antibodies is answerable for their protecting perform and long-lasting serum half-life by way of Fc-mediated effector perform, transcytosis, and recycling by its interplay with Fc receptors (FcRs) expressed on varied immune leukocytes, epithelial, and endothelial cells. Due to this fact, the Fc-FcRs interplay is a management level of each endogenous and therapeutic antibody perform.
There are a variety of reported genetic variants of FcRs, which embrace polymorphisms in (i) extracellular area of FcRs, which change their affinities to Fc area of antibodies; (ii) each cytoplasmic and intracellular area, which alters the extent of sign transduction; and (iii) the promoter area of the FcRs gene, which impacts the expression degree of FcRs, thus being related to the pathogenesis of illness indications.
On this assessment, we firstly describe the correlation between the genetic variants of FcRs and immunological problems by particular person variations within the extent of FcRs-mediated laws. Secondly, we focus on the affect of the genetic variants of FcRs on the susceptibility to infectious ailments or most cancers within the perspective of FcRs-induced effector capabilities. General, we concluded that the genetic variants of FcRs are one of many key components within the design of antibody therapeutics as a consequence of their number of medical outcomes amongst people.
SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies Could Ameliorate COVID-19 Issues in APECED Sufferers
Sufferers with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is brought on by loss-of-function mutations within the autoimmune regulator (AIRE) gene, uniformly carry neutralizing autoantibodies directed in opposition to type-I interferons (IFNs) and lots of develop autoimmune pneumonitis, each of which place them at excessive threat for life-threatening COVID-19 pneumonia.
Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that focus on the SARS-CoV-2 spike protein and block entry of SARS-CoV-2 in host cells. Using bamlanivimab and etesevimab early throughout an infection was related to lowered COVID-19-associated hospitalization and dying in sufferers at excessive threat for progressing to extreme illness, which led the US Meals and Drug Administration to subject an emergency use authorization for his or her administration in non-hypoxemic, non-hospitalized high-risk sufferers.
Nevertheless, the protection and efficacy of those mAbs has not been evaluated in APECED sufferers. We enrolled two siblings with APECED on an IRB-approved protocol and admitted them prophylactically on the NIH Medical Heart for analysis of mild-to-moderate COVID-19. We assessed the protection and medical results of early therapy with bamlanivimab and etesevimab.
The administration of bamlanivimab and etesevimab was effectively tolerated and was related to amelioration of COVID-19 signs and prevention of invasive ventilatory help, admission to the intensive care, and dying in each sufferers with out affecting the manufacturing of antibodies to the nucleocapsid protein of SARS-CoV-2.
If given early in the midst of COVID-19 an infection, bamlanivimab and etesevimab could also be useful in APECED and different high-risk sufferers with neutralizing autoantibodies directed in opposition to type-I IFNs.
Case Report: Full Response of Main Large Hepatocellular Carcinoma to Anti-Programmed Demise Ligand-1 Antibody Following Development on Anti-Programmed Demise-1 Antibody
Hepatocellular carcinoma (HCC) is an aggressive liver tumor that happens as a consequence of persistent liver illness, and it has a excessive mortality charge and restricted therapy choices. Immune checkpoint inhibitors have been efficiently launched and utilized in most cancers remedy, amongst which inhibitors of programmed dying ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are generally administered for HCC as mixture remedy, together with mixed anti-angiogenic and immunotherapy mixture remedy.
We report a case of a main large HCC affected person with portal hepatic vein tumor thrombus who had a great response to atezolizumab together with bevacizumab, following development of illness on mixed immunotherapy with pembrolizumab and lenvatinib.
 Mouse mAb) CD54 (ABT-CD54) Mouse mAb |
|
E2252816 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CD54 (ABT-CD54) Mouse mAb |
|
MBS8541371-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CD54 (ABT-CD54) Mouse mAb |
|
MBS8541371-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
CD54 (ABT-CD54) Mouse mAb |
|
MBS8541371-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
CD54 (ABT-CD54) Mouse mAb |
|
MBS8541371-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
CD54 (ABT-CD54) Mouse mAb |
|
MBS8541371-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 mouse mAb) CD54 (ABT-CD54) mouse mAb |
|
UB-GEN-14950 |
UpingBio |
100 ul |
EUR 200 |
 Mouse mAb) CD54 (Clone ENG-CD54) Mouse mAb |
|
E11-126573 |
EnoGene |
100ug/100ul |
EUR 275 |
 CD54 PE |
|
MBS396537-100Tests |
MyBiosource |
100Tests |
EUR 325 |
CD54 PE |
|
MBS396537-5x100Tests |
MyBiosource |
5x100Tests |
EUR 1305 |
 ICAM1/CD54 |
|
E8ER1910-98 |
EnoGene |
100ul |
EUR 275 |
|
Description: Available in various conjugation types. |
ICAM1/CD54 |
|
MBS8577788-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
ICAM1/CD54 |
|
MBS8577788-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
ICAM1/CD54 |
|
MBS8577788-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
ICAM1/CD54 |
|
MBS8577788-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 CD54 Biotin |
|
MBS396523-100Tests |
MyBiosource |
100Tests |
EUR 310 |
CD54 Biotin |
|
MBS396523-5x100Tests |
MyBiosource |
5x100Tests |
EUR 1250 |
 CD54 antibody |
|
70R-13774 |
Fitzgerald |
100 ug |
EUR 519 |
|
|
|
Description: Affinity purified Rabbit polyclonal CD54 antibody |
CD54 antibody |
|
70R-49888 |
Fitzgerald |
100 ul |
EUR 286 |
|
|
|
Description: Purified Polyclonal CD54 antibody |
CD54 antibody |
|
70R-49889 |
Fitzgerald |
100 ul |
EUR 242 |
|
|
|
Description: Purified Polyclonal CD54 antibody |
CD54 antibody |
|
10R-CD54aHU |
Fitzgerald |
100 ug |
EUR 449 |
|
|
|
Description: Mouse monoclonal CD54 antibody |
CD54 antibody |
|
10R-6420 |
Fitzgerald |
100 ug |
EUR 120 |
|
|
|
Description: Mouse monoclonal CD54 antibody |
 CD54 Antibody |
|
abx228232-100g |
Abbexa |
100 µg |
EUR 62.5 |
CD54 Antibody |
|
E90307 |
EnoGene |
100ul |
EUR 255 |
|
Description: Available in various conjugation types. |
CD54 Antibody |
|
E38PA9666 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CD54 Antibody |
|
E38PA9767 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CD54 Antibody |
|
E38PA1570 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CD54 Antibody |
|
E10-31462 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CD54 Antibody |
|
E10-31463 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CD54 Antibody |
|
MBS5312592-01mg |
MyBiosource |
0.1mg |
EUR 975 |
CD54 Antibody |
|
MBS5312592-5x01mg |
MyBiosource |
5x0.1mg |
EUR 4245 |
CD54 antibody |
|
MBS530386-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3295 |
CD54 Antibody |
|
MBS5314508-01mL |
MyBiosource |
0.1mL |
EUR 535 |
CD54 Antibody |
|
MBS5314508-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2270 |
CD54 Antibody |
|
MBS5314509-01mL |
MyBiosource |
0.1mL |
EUR 470 |
CD54 Antibody |
|
MBS5314509-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1955 |
CD54 Antibody |
|
MBS8500410-01mL |
MyBiosource |
0.1mL |
EUR 325 |
CD54 Antibody |
|
MBS8500410-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
CD54 Antibody |
|
MBS8500410-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
CD54 Antibody |
|
MBS8500410-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
CD54 Antibody |
|
MBS8500410-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
CD54 Antibody |
|
MBS8584467-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CD54 Antibody |
|
MBS8584467-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
CD54 Antibody |
|
MBS8584467-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
CD54 Antibody |
|
MBS8584467-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
CD54 Antibody |
|
MBS8584467-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
CD54 Antibody |
|
MBS8584568-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CD54 Antibody |
|
MBS8584568-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
CD54 Antibody |
|
MBS8584568-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
CD54 Antibody |
|
MBS8584568-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
CD54 Antibody |
|
MBS8584568-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
CD54 Antibody |
|
MBS8580698-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CD54 Antibody |
|
MBS8580698-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
CD54 Antibody |
|
MBS8580698-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
CD54 Antibody |
|
MBS8580698-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
CD54 Antibody |
|
MBS8580698-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
 mouse mAb Ready to use) CD54 (ABT-CD54) mouse mAb Ready to use |
|
UB-GEN-16896 |
UpingBio |
100 ul |
EUR 200 |
 CD54/ICAM-1 |
|
MBS4380988-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
CD54/ICAM-1 |
|
MBS4380988-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
CD54/ICAM-1 |
|
MBS4380988-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
CD54/ICAM-1 |
|
MBS4380988-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
CD54/ICAM-1 |
|
MBS4380988-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
 CD54, ICAM-1 |
|
MBS397058-5x01mg |
MyBiosource |
5x0.1mg |
EUR 4015 |
) CD54 (ICAM-1) |
|
MBS378121-5x05mg |
MyBiosource |
5x0.5mg |
EUR 1550 |
 ICAM-1/CD54 |
|
PR27037-B |
Neuromics |
each |
EUR 184.5 |
 CD54 Mouse mAb |
|
E2222509 |
EnoGene |
100ul |
EUR 255 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CD54 Mouse mAb |
|
MBS4753731-01mL |
MyBiosource |
0.1mL |
EUR 450 |
CD54 Mouse mAb |
|
MBS4753731-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1540 |
) CD54 Antibody (PE) |
|
abx228235-100g |
Abbexa |
100 µg |
EUR 50 |
CD54 Antibody (PE) |
|
abx228424-100g |
Abbexa |
100 µg |
EUR 100 |
 Mouse Human CD54 |
|
E2790160 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Mouse Human CD54 |
|
MBS8559207-01mL |
MyBiosource |
0.1mL |
EUR 305 |
Mouse Human CD54 |
|
MBS8559207-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Mouse Human CD54 |
|
MBS8559207-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Mouse Human CD54 |
|
MBS8559207-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Mouse Human CD54 |
|
MBS8559207-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
) CD54 Antibody (APC) |
|
abx228236-100g |
Abbexa |
100 µg |
EUR 50 |
CD54 Antibody (APC) |
|
abx228425-100g |
Abbexa |
100 µg |
EUR 100 |
) CD54 Antibody (FITC) |
|
abx139538-100l |
Abbexa |
100 µl |
EUR 350 |
CD54 Antibody (FITC) |
|
abx139538-100tests |
Abbexa |
100 tests |
EUR 510 |
|
|
CD54 Antibody (FITC) |
|
abx139538-500l |
Abbexa |
500 µl |
Ask for price |
CD54 Antibody (FITC) |
|
abx228234-100g |
Abbexa |
100 µg |
EUR 50 |
CD54 Antibody (FITC) |
|
abx228423-100g |
Abbexa |
100 µg |
EUR 93.75 |
CD54 Antibody (FITC) |
|
GWB-72853B |
GenWay Biotech |
100 TESTS |
Ask for price |
 Antibody) CD54 (pT512) Antibody |
|
20-abx009840 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
 ICAM1/CD54 Antibody |
|
35344 |
SAB |
100ul |
EUR 479 |
ICAM1/CD54 Antibody |
|
35344-100ul |
SAB |
100ul |
EUR 468 |
) CD54 Antibody (AF488) |
|
abx228242-100g |
Abbexa |
100 µg |
EUR 62.5 |
) CD54 Antibody (AF647) |
|
abx228243-100g |
Abbexa |
100 µg |
EUR 62.5 |
ICAM1/CD54 Antibody |
|
MBS9404902-01mL |
MyBiosource |
0.1mL |
EUR 420 |
ICAM1/CD54 Antibody |
|
MBS9404902-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1740 |
) CD54 antibody (biotin) |
|
61R-1516 |
Fitzgerald |
100 ug |
EUR 420 |
|
|
|
Description: Mouse monoclonal CD54 antibody (biotin) |
) CD54 Antibody (Biotin) |
|
abx139537-01mg |
Abbexa |
0.1 mg |
EUR 510 |
|
|
CD54 Antibody (Biotin) |
|
abx139537-100l |
Abbexa |
100 µl |
EUR 350 |
CD54 Antibody (Biotin) |
|
abx139537-500l |
Abbexa |
500 µl |
Ask for price |
CD54 Antibody (Biotin) |
|
abx228233-100g |
Abbexa |
100 µg |
EUR 75 |
CD54 Antibody (Biotin) |
|
GWB-1D291D |
GenWay Biotech |
0.02 mg |
Ask for price |
 CD54-muIg-Biotin |
|
MBS666833-0025mg |
MyBiosource |
0.025mg |
EUR 685 |
CD54-muIg-Biotin |
|
MBS666833-5x0025mg |
MyBiosource |
5x0.025mg |
EUR 2935 |
 Antibody) CD54 (PT0050) Antibody |
|
N1777-100uL |
Assay Biotech |
100uL |
EUR 122.5 |
|
Description: Human CD54 (PT0050) Mouse Monoclonal Antibody |
CD54 (PT0050) Antibody |
|
N1777-50uL |
Assay Biotech |
50uL |
EUR 66.5 |
|
Description: Human CD54 (PT0050) Mouse Monoclonal Antibody |
 Antibody) CD54 (ABT149) Antibody |
|
V0244-100uL |
Assay Biotech |
100uL |
EUR 122.5 |
|
Description: Human CD54 (ABT149) Mouse Monoclonal Antibody |
CD54 (ABT149) Antibody |
|
V0244-50uL |
Assay Biotech |
50uL |
EUR 66.5 |
|
Description: Human CD54 (ABT149) Mouse Monoclonal Antibody |
 Antibody) CD54 (ABT432) Antibody |
|
V0245-100uL |
Assay Biotech |
100uL |
EUR 122.5 |
|
Description: Human CD54 (ABT432) Mouse Monoclonal Antibody |
CD54 (ABT432) Antibody |
|
V0245-50uL |
Assay Biotech |
50uL |
EUR 66.5 |
|
Description: Human CD54 (ABT432) Mouse Monoclonal Antibody |
 CD54 Blocking Peptide |
|
20-abx062764 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
CD54 Blocking Peptide |
|
MBS823660-1mg |
MyBiosource |
1mg |
EUR 190 |
CD54 Blocking Peptide |
|
MBS823660-5mg |
MyBiosource |
5mg |
EUR 345 |
CD54 Blocking Peptide |
|
MBS823660-5x5mg |
MyBiosource |
5x5mg |
EUR 1465 |
 RECOMBINANT HUMAN CD54 |
|
MBS232503-005mg |
MyBiosource |
0.05mg |
EUR 510 |
RECOMBINANT HUMAN CD54 |
|
MBS232503-5x005mg |
MyBiosource |
5x0.05mg |
EUR 2130 |
 CD54 Polyclonal Antibody |
|
E-AB-13130-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-13130-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-13130-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-13130-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-14711-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-14711-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-14711-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-14711-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-16322-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-16322-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-16322-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-16322-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
|
|
Description: Unconjugated |
 CD54 polyclonal antibody |
|
BS67788 |
Bioworld Biotech |
50ul |
EUR 275 |
|
|
|
Description: Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
CD54 Polyclonal Antibody |
|
E-AB-70046-120uL |
Elabscience Biotech |
120uL |
EUR 260 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-70046-200uL |
Elabscience Biotech |
200uL |
EUR 410 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-70046-60uL |
Elabscience Biotech |
60uL |
EUR 160 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-70046-each |
Elabscience Biotech |
each |
Ask for price |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-31758-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-31758-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-31758-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
|
|
Description: Unconjugated |
CD54 Polyclonal Antibody |
|
E-AB-31758-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
|
|
Description: Unconjugated |
 CD54 monoclonal antibody |
|
MB65793 |
Bioworld Biotech |
50ul |
EUR 275 |
|
|
|
Description: Mouse IgG1. Liquid in PBS, pH 7.3, and 0.02% sodium azide. |
CD54 monoclonal antibody |
|
MB66051 |
Bioworld Biotech |
50ul |
EUR 275 |
|
|
|
Description: Mouse IgG. Liquid in PBS containing 50% glycerol, 0.2% BSA and 0.01% sodium azide. |
CD54 monoclonal antibody |
|
MB66152 |
Bioworld Biotech |
50ul |
EUR 275 |
|
|
|
Description: Mouse IgG1. Liquid in PBS containing 50% glycerol, 0.2% BSA and 0.01% sodium azide. |
CD54 monoclonal antibody |
|
MB66655 |
Bioworld Biotech |
50ul |
EUR 275 |
|
|
|
Description: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3. |
CD54 monoclonal antibody |
|
MB66656 |
Bioworld Biotech |
50ul |
EUR 275 |
|
|
|
Description: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide, pH 7.3. |
CD54 Polyclonal Antibody |
|
MBS2555127-006mL |
MyBiosource |
0.06mL |
EUR 180 |
CD54 Polyclonal Antibody |
|
MBS2555127-012mL |
MyBiosource |
0.12mL |
EUR 260 |
CD54 Polyclonal Antibody |
|
MBS2555127-02mL |
MyBiosource |
0.2mL |
EUR 405 |
This case demonstrates for the primary time that an HCC affected person who’s proof against anti-PD-1 antibody immunotherapy can profit from anti-PD-L1 antibody immunotherapy, offering a probably promising technique for the therapy of HCC.
